Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and myasthenia gravis are now recruiting.
Date | Form | Description | XBRL | Pages | |
---|---|---|---|---|---|
05/15/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
110 |
11/09/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
116 |
08/10/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
114 |
05/11/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
127 |
11/10/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
151 |
08/11/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
105 |
05/12/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
101 |
11/01/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
106 |
08/05/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
96 |
05/03/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
97 |